(Q50700447)

English

Identification of early predictive imaging biomarkers and their relationship to serological angiogenic markers in patients with ovarian cancer with residual disease following cytotoxic therapy

scientific article published on 29 March 2010

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/20351070

Identification of early predictive imaging biomarkers and their relationship to serological angiogenic markers in patients with ovarian cancer with residual disease following cytotoxic therapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/20351070

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

14

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/20351070

Gordon C. Jayson

15

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/20351070

author name string

C L Mitchell

1

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/20351070

J P B O'Connor

2

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/20351070

A Jackson

3

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/20351070

G J M Parker

4

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/20351070

C Roberts

5

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/20351070

Y Watson

6

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/20351070

S Cheung

7

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/20351070

K Davies

8

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/20351070

G A Buonaccorsi

9

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/20351070

A R Clamp

10

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/20351070

J Hasan

11

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/20351070

L Byrd

12

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/20351070

A Backen

13

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/20351070

publication date

29 March 2010

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/20351070

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/20351070

21

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/20351070

10

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/20351070

1982-1989

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/20351070

Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ079

21 January 2018

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ079

21 January 2018

Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ079

21 January 2018

Phase I evaluation of CDP791, a PEGylated di-Fab' conjugate that binds vascular endothelial growth factor receptor 2.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ079

21 January 2018

Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ079

21 January 2018

Rapid calculation of T1 using variable flip angle gradient refocused imaging.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ079

21 January 2018

Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ079

21 January 2018

Enhancing fraction predicts clinical outcome following first-line chemotherapy in patients with epithelial ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ079

21 January 2018

Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ079

21 January 2018

Modeling tracer kinetics in dynamic Gd-DTPA MR imaging

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ079

21 January 2018

Experimentally-derived functional form for a population-averaged high-temporal-resolution arterial input function for dynamic contrast-enhanced MRI.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ079

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ079

21 January 2018

Recent developments in the regulation of the angiogenic switch by cellular stress factors in tumors

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ079

21 January 2018

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ079

21 January 2018

‘Fit-for-purpose’ validation of SearchLight multiplex ELISAs of angiogenesis for clinical trial use

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDQ079

21 January 2018

Identifiers

10.1093/ANNONC/MDQ079

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/20351070

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 March 2018

http://europepmc.org/abstract/MED/20351070

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50700447&oldid=2259643762"